Page last updated: 2024-11-02

pioglitazone and Acute Ischemic Stroke

pioglitazone has been researched along with Acute Ischemic Stroke in 9 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
"Pioglitazone use is associated with a lower risk of dementia in patients with DM, particularly in those with a history of stroke or ischemic heart disease, suggesting the possibility of applying a personalized approach when choosing pioglitazone to suppress dementia in patients with DM."8.31Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke. ( Choi, DW; Ha, J; Kim, E; Kim, KJ; Kim, KY; Nam, CM, 2023)
"In T2D patients with ischemic stroke, lobeglitazone reduced the risk of cardiovascular complications similar to that of pioglitazone without an increased risk of HF."8.31Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study. ( Baik, M; Jeon, J; Kim, J; Yoo, J, 2023)
"Using longitudinal nationwide data from the 2002-2017 Korean National Health Insurance Service DM cohort, we analyzed the association between pioglitazone use and incidence of primary ischemic stroke using a nested case-control study."8.02Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study. ( Choi, DW; Ha, J; Kim, E; Kim, KY; Nam, CM, 2021)
"Participants were enrolled in the Insulin Resistance Intervention after Stroke trial, which examined the insulin sensitiser, pioglitazone versus placebo for prevention of stroke and myocardial infarction after ischaemic stroke or transient ischaemic attack."5.22Taking care of volunteers in a stroke trial: a new assisted-management strategy. ( Cote, R; Ford, GA; Furie, KL; Inzucchi, SE; Kernan, WN; Sico, JJ; Spence, JD; Stuart, AC; Tanne, D; Tayal, AH; Viscoli, CM, 2016)
"Pioglitazone use is associated with a lower risk of dementia in patients with DM, particularly in those with a history of stroke or ischemic heart disease, suggesting the possibility of applying a personalized approach when choosing pioglitazone to suppress dementia in patients with DM."4.31Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke. ( Choi, DW; Ha, J; Kim, E; Kim, KJ; Kim, KY; Nam, CM, 2023)
"In T2D patients with ischemic stroke, lobeglitazone reduced the risk of cardiovascular complications similar to that of pioglitazone without an increased risk of HF."4.31Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study. ( Baik, M; Jeon, J; Kim, J; Yoo, J, 2023)
"Using longitudinal nationwide data from the 2002-2017 Korean National Health Insurance Service DM cohort, we analyzed the association between pioglitazone use and incidence of primary ischemic stroke using a nested case-control study."4.02Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study. ( Choi, DW; Ha, J; Kim, E; Kim, KY; Nam, CM, 2021)
"The treatment of reperfusion injury after ischemic stroke remains unsatisfactory since the blood-brain barrier (BBB) prevents most neuroprotective agents from entering the brain."1.91Bacteria-Derived Outer-Membrane Vesicles Hitchhike Neutrophils to Enhance Ischemic Stroke Therapy. ( Guo, X; Huang, X; Pan, J; Wang, Z; Xue, J; Zhang, S; Zhou, S, 2023)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (11.11)24.3611
2020's8 (88.89)2.80

Authors

AuthorsStudies
Guo, Y1
Zuo, W1
Yin, L1
Gu, T1
Wang, S1
Fang, Z1
Wang, B1
Dong, H1
Hou, W1
Zuo, Z1
Deng, J1
Ha, J2
Choi, DW2
Kim, KJ1
Kim, KY2
Nam, CM2
Kim, E3
Yoo, J1
Jeon, J1
Baik, M1
Kim, J1
Feng, Q1
Lewis, A1
Galetta, S1
Pan, J1
Wang, Z1
Huang, X1
Xue, J1
Zhang, S1
Guo, X1
Zhou, S1
Stuart, AC1
Sico, JJ1
Viscoli, CM1
Tayal, AH1
Inzucchi, SE1
Ford, GA1
Furie, KL1
Cote, R1
Spence, JD1
Tanne, D1
Kernan, WN1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Insulin Resistance Intervention After Stroke (IRIS) Trial[NCT00091949]Phase 33,876 participants (Actual)Interventional2005-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Acute Coronary Syndrome

Fatal or non-fatal acute myocardial infarction or unstable angina (NCT00091949)
Timeframe: 5 years

Interventionparticipants (Number)
Pioglitazone206
Placebo249

All Cause Mortality

(NCT00091949)
Timeframe: 5 years

Interventionparticipants (Number)
Pioglitazone136
Placebo146

Composite Outcome of Fatal or Non-fatal Stroke, Fatal or Non-fatal MI or Episode of Serious Congestive Heart Failure

(NCT00091949)
Timeframe: 5 years

Interventionparticipants (Number)
Pioglitazone206
Placebo249

Decline in Cognitive Status

Change in modified mental status examination (3MS) score from baseline to exit. Theoretical range of 3MS scores is 0-100. Baseline scores ranged from 22-100. (NCT00091949)
Timeframe: Annual measures from baseline to exit (up to 5 years)

Interventionunits on a scale (Mean)
Pioglitazone0.27
Placebo0.29

Development of Overt Diabetes

(NCT00091949)
Timeframe: 5 years

Interventionparticipants (Number)
Pioglitazone73
Placebo149

Fatal or Non-fatal Stroke Alone

(NCT00091949)
Timeframe: 5 years

Interventionparticipants (Number)
Pioglitazone127
Placebo154

Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction

(NCT00091949)
Timeframe: Up to 5 years

Interventionparticipants (Number)
Pioglitazone175
Placebo228

Trials

1 trial available for pioglitazone and Acute Ischemic Stroke

ArticleYear
Taking care of volunteers in a stroke trial: a new assisted-management strategy.
    Stroke and vascular neurology, 2016, Volume: 1, Issue:3

    Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Biomarkers; Blood Coagulation; Blood Pressu

2016

Other Studies

8 other studies available for pioglitazone and Acute Ischemic Stroke

ArticleYear
Pioglitazone attenuates ischaemic stroke aggravation by blocking PPARĪ³ reduction and inhibiting chronic inflammation in diabetic mice.
    The European journal of neuroscience, 2022, Volume: 56, Issue:6

    Topics: Animals; Brain Ischemia; Diabetes Mellitus, Experimental; Inflammation; Ischemic Stroke; Mice; NLR F

2022
Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
    Neurology, 2023, 04-25, Volume: 100, Issue:17

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Ischemic Stroke; Myocardial Ischemia; Piogli

2023
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study.
    Cardiovascular diabetology, 2023, 05-05, Volume: 22, Issue:1

    Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin

2023
Reader Response: Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
    Neurology, 2023, 06-13, Volume: 100, Issue:24

    Topics: Dementia; Diabetes Mellitus; Humans; Ischemic Stroke; Patients; Pioglitazone

2023
Editors' Note: Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
    Neurology, 2023, 06-13, Volume: 100, Issue:24

    Topics: Dementia; Diabetes Mellitus; Humans; Ischemic Stroke; Patients; Pioglitazone

2023
Author Response: Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke.
    Neurology, 2023, 06-13, Volume: 100, Issue:24

    Topics: Dementia; Diabetes Mellitus; Humans; Ischemic Stroke; Patients; Pioglitazone

2023
Bacteria-Derived Outer-Membrane Vesicles Hitchhike Neutrophils to Enhance Ischemic Stroke Therapy.
    Advanced materials (Deerfield Beach, Fla.), 2023, Volume: 35, Issue:38

    Topics: Bacteria; Extracellular Vesicles; Humans; Ischemic Stroke; Neutrophils; Pioglitazone; Reperfusion In

2023
Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study.
    Cardiovascular diabetology, 2021, 07-27, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2;

2021